The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
December 8th 2024
The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Avella Specialty Pharmacy: Overcoming Oncology Adherence Barriers
June 18th 2013Specialty Pharmacy Times sat down to talk with Dr. Eric Sredzinski about the controversial topic of pricing for oncology medications, as well as common patient reimbursement hurdles and Avella's technologically savvy efforts to break down patient adherence barriers.
Read More
Welcome to our third annual special Oncology edition of Specialty Pharmacy Times! While new targeted oral medications are convenient and effective, they are also expensive and toxic, so the need for creating the greatest effectiveness from therapy is warranted. That's where specialty pharmacy comes in.
Read More
Specialty Pharmacy Times Focuses on Oncology Trends
February 16th 2013Specialty Pharmacy Times announces the addition of a new department, Oncology Trends. This section will focus on the management of oncology medications under the pharmacy and medical benefits, clinical pathways, pharmacogenomic and companion testing, and clinical practice guidelines in oncology.
Read More
Delivering Evidence-Based Value to Cancer Patients
February 15th 2013Specialty Pharmacy Times spoke with Dr. Neubauer to discuss the intricacies of clinical pathways, including how to reconcile a drug's cost and benefits, the importance of making evidence-based decisions, when to deviate from recommended treatment pathways, and why he thinks all health plans should pay for the routine costs of clinical trials.
Read More
Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care
December 12th 2012Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
Read More
Medicare Could Have Saved $33 Million on Prostate Cancer Drugs
November 28th 2012By prescribing clinically similar luteinizing hormone–releasing hormone agonists for the treatment of prostate cancer, Medicare could have saved 13% of its total budget for monthly injections, according to a study from the Office of the Inspector General.
Read More
Sanofi Halves the Price of Zaltrap in Response to Criticism from Oncologists
November 13th 2012Sanofi slashed the price of colorectal cancer drug Zaltrap (ziv-aflibercept) in half after 2 oncologists from Memorial Sloan-Kettering Cancer Center publicly balked at the drug's $11,000 price tag in an op-ed in The New York Times.
Read More